Adjective
neurocrine (not comparable)
Describing a paracrine hormone released from neuronal cells
Finally, Morgan Stanley decreased their target price on shares of Neurocrine Biosciences from $149.00 to $146.00 and set an “overweight” rating for the company in a research report on Tuesday, August 4th. Source: Internet
Neurocrine Biosciences has an average rating of “Buy” and a consensus target price of $137. Source: Internet